Group 1 - The core viewpoint of the news is that NuoVaxan's stock has shown a slight increase, with a closing price of 22.49 yuan, reflecting a 1.90% rise and a market capitalization of 8.945 billion yuan [1] - As of March 31, 2025, NuoVaxan has 8,397 shareholders, an increase of 671 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - NuoVaxan's main business focuses on the research and development of functional proteins and high molecular organic materials, with key products including biological reagents, diagnostic reagents, equipment, technical services, and consumables [1] Group 2 - In the latest quarterly report for Q1 2025, NuoVaxan reported a revenue of 285 million yuan, representing a year-on-year decrease of 5.50%, and a net profit of 1.9099 million yuan, down 63.39% year-on-year, with a gross profit margin of 69.40% [1] - The company's price-to-earnings (PE) ratio is significantly negative at -417.99 (TTM) and -494.37 (static), while the industry average PE is 48.90 (TTM) and 47.00 (static) [2] - The market valuation of NuoVaxan is 8.945 billion yuan, with a price-to-book ratio of 2.29, compared to the industry median of 2.40 [2]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-020 南京诺唯赞生物科技股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2024年年度股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 19 日至2025 年 5 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 1 股东会召开日期：2025年5月19日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-019 南京诺唯赞生物科技股份有限公司 第二届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司(以下简称"公司")第二届监事会第十四 次会议（以下简称"会议"）于 2025 年 4 月 22 日以邮件的方式向全体监事发出 会议通知，并于 2025 年 4 月 28 日以通讯表决方式召开。本次会议由公司第二届 监事会主席张国洋先生主持，应出席监事 3 人，实际出席监事 3 人。本次会议的 通知、召开及审议程序符合《公司法》等有关法律法规及《公司章程》的规定。 会议审议通过如下议案： 审议通过《2025 年度第一季度报告》 监事会认为，公司 2025 年第一季度报告的编制和审议程序符合相关法律法 规及《公司章程》等内部规章制度的规定，内容与格式符合相关规定，真实、准 确、完整地反映了公司 2025 年第一季度的财务状况和经营成果等事项，不存在 任何虚假记载、误导性陈述或重大遗漏。在 2025 年第一季度报告编 ...

前十大流通股东累计持有： 30401.83万股，累计占流通股比： 76.44%，较上期变化： -65.12万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 南京诺唯赞投资管理有限公司 | 16190.73 | 40.71 | 不变 | | 国寿成达(上海)健康产业股权投资中心(有限合伙) | 3095.80 | 7.78 | 不变 | | 杨奇 | 2187.29 | 5.50 | 不变 | | 曹林 | 2138.90 | 5.38 | 不变 | | 南京博英维创业投资合伙企业(有限合伙) | 1442.83 | 3.63 | 不变 | | 深圳旦恩先锋投资管理有限公司-深圳旦恩创业投资合伙 企业(有限合伙) | 1330.64 | 3.35 | -54.54 | | 南京唯赞创业投资合伙企业(有限合伙) | 1275.88 | 3.21 | 不变 | | 南京诺泰创业投资合伙企业(有限合伙) | 1174.25 | 2.95 | -10.58 | | 珠海广发信德敖东医药产业股权投资中心 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥284,980,795.58, a decrease of 5.50% compared to ¥301,571,120.22 in the same period last year[4] - Net profit attributable to shareholders decreased by 63.39% to ¥1,909,911.67 from ¥5,216,369.89 year-on-year[4] - Basic and diluted earnings per share both fell by 50.00% to ¥0.005 from ¥0.01 in the previous year[4] - Total revenue for Q1 2025 was CNY 284,980,795.58, a decrease of 5.2% compared to CNY 301,571,120.22 in Q1 2024[17] - Net profit for Q1 2025 was CNY 1,856,553.27, compared to CNY 4,875,266.29 in Q1 2024, indicating a decline in profitability[18] - The total comprehensive income attributable to the parent company was CNY 3,518,626.02, down from CNY 4,977,050.35 in the previous year, representing a decrease of approximately 29.3%[19] - The company's revenue for Q1 2025 was ¥226,819,281.26, a decrease of 6.5% compared to ¥243,334,887.78 in Q1 2024[25] - Operating profit for Q1 2025 was ¥11,221,646.94, an increase of 7.7% from ¥10,420,588.13 in Q1 2024[26] - Net profit for Q1 2025 reached ¥14,170,607.93, up 2.9% from ¥13,771,348.09 in Q1 2024[26] Research and Development - Research and development expenses totaled ¥66,468,634.05, accounting for 23.32% of operating revenue, a slight decrease of 0.14 percentage points from the previous year[5] - The company reported a decrease in R&D expenses to CNY 66,468,634.05 in Q1 2025 from CNY 70,762,810.52 in Q1 2024, reflecting a focus on cost management[18] - Research and development expenses for Q1 2025 were ¥39,446,368.24, a decrease of 15.6% compared to ¥46,711,723.79 in Q1 2024[26] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥55,017,260.08, an improvement from -¥81,496,867.29 in the previous year[4] - The company's cash and cash equivalents increased to CNY 475,664,910.64 as of March 31, 2025, up from CNY 434,245,326.54 at the end of 2024[13] - The company's cash and cash equivalents at the end of Q1 2025 were CNY 295,911,908.80, down from CNY 908,855,353.96 at the end of Q1 2024[21] - The company reported a net cash flow from operating activities of -¥112,451,869.82 in Q1 2025, an improvement from -¥213,556,683.45 in Q1 2024[29] - The company achieved cash inflow from operating activities totaling ¥1,317,875,880.11 in Q1 2025, significantly higher than ¥199,112,075.59 in Q1 2024[29] - The company reported a decrease in cash flow from financing activities, with a net cash flow of CNY 298,778,467.60 in Q1 2025, compared to negative CNY 334,738,672.19 in Q1 2024[21] Assets and Liabilities - Total assets increased by 4.31% to ¥5,266,304,774.25 compared to ¥5,048,663,079.32 at the end of the previous year[5] - Total assets reached CNY 5,266,304,774.25 as of March 31, 2025, an increase from CNY 5,048,663,079.32 at the end of 2024[14] - Total liabilities increased to CNY 1,365,454,324.70 as of March 31, 2025, compared to CNY 1,105,054,200.00 at the end of 2024[15] - The company's long-term assets decreased to CNY 1,403,369,783.38 as of March 31, 2025, down from CNY 1,477,191,932.56 at the end of 2024[14] - The company's total equity decreased to CNY 3,900,850,449.55 as of March 31, 2025, from CNY 3,943,608,879.32 at the end of 2024[15] - The total current assets amounted to CNY 4,597,540,249.41, an increase from CNY 4,233,836,352.31 in the previous year[23] Investments and Acquisitions - The company acquired a 6.99% stake in Jiangsu Liquid Logic Biotechnology Co., Ltd., bringing its total ownership to 98.42%[10] - The company invested ¥5 million to subscribe for a 0.7825% stake in Suzhou Huiliao Biomedical Technology Co., Ltd.[10] - The company also invested ¥5 million to acquire a 1.6393% stake in Nanjing Lingxin Biotechnology Co., Ltd.[10] - The establishment of a subsidiary, Nanjing Liquid Droplet Biotechnology Co., Ltd., was completed with a registered capital of $7 million, fully owned by LOGILET(UK)[10] Financial Ratios - Basic and diluted earnings per share for Q1 2025 were both ¥0.04, an increase from ¥0.03 in Q1 2024[26]

证券代码:688105 证券简称:诺唯赞 公告编号:2025-021 南京诺唯赞生物科技股份有限公司 关于召开2024年度暨2025年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）已分别于 2025 年 4 月 10 日、2025 年 4 月 29 日发布公司 2024 年年度报告、公司 2025 年第一季度 报告，为便于广大投资者更全面深入地了解公司 2024 年度及 2025 年第一季度经 营成果、财务状况，公司计划于 2025 年 5 月 9 日上午 11：00-12：00 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 1 会议召开时间 ...

Group 1 - The Alzheimer's concept sector rose by 1.30%, ranking 6th among concept sectors, with 21 stocks increasing in value [1][2] - Notable gainers in the sector included Jinkai Biotechnology with a 20% limit-up, Shuangcheng Pharmaceutical also hitting the limit-up, and LuKang Pharmaceutical, Fujilai, and Dongcheng Pharmaceutical with increases of 3.95%, 3.60%, and 2.06% respectively [1][2] - The sector experienced a net inflow of 250 million yuan from main funds, with Shuangcheng Pharmaceutical leading the inflow at 181 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Jinkai Biotechnology at 33.12%, Shuangcheng Pharmaceutical at 19.33%, and Chitianhua at 5.51% [3] - The trading volume and turnover rates for key stocks in the Alzheimer's concept were significant, with Shuangcheng Pharmaceutical showing a turnover rate of 23.40% and Jinkai Biotechnology at 23.43% [3] - Decliners in the sector included NuoVizon, Dean Diagnostics, and BGI Genomics, with declines of 2.96%, 2.68%, and 1.85% respectively [1][4]

华泰联合证券有限责任公司 关于南京诺唯赞生物科技股份有限公司 2024 年度持续督导跟踪报告 根据《证券法》、《证券发行上市保荐业务管理办法》和《上海证券交易所 科创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐人"）作为南京诺唯赞生物科技股份有限公司（以 下简称"诺唯赞"、"公司"或"发行人"）持续督导的保荐人，负责诺唯赞上市后的 持续督导工作，并出具本年度持续督导跟踪报告。 一、保荐人和保荐代表人发现的问题及整改情况 无。 生物试剂行业和体外诊断行业均为技术密集型行业。在后续新产品研发过程 中，公司可能面临因研发技术路线出现偏差、研发成本投入过高、研发进程缓慢 而导致产品研发失败的风险，若不能持续及时研发出满足不同市场需求的产品与 服务，公司可能会错失市场机会，进而对公司的经营规模、盈利能力等方面造成 不利影响。 自设立以来，公司坚持从底层技术出发的自主研发，不断完善与巩固核心共 性技术平台，逐步从生物试剂领域进入到体外诊断、疫苗临床CRO服务、疫苗原 1 二、重大风险事项 公司目前面临的风险因素主要如下： （一）核心竞争力风险 1、产品研发与技术迭代 ...

保荐总结报告书 华泰联合证券有限责任公司 关于南京诺唯赞生物科技股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 | 保荐机构名称 华泰联合证券有限责任公司 | | --- | | 保荐机构编号 Z26774000 | 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 保荐总结报告书 三、发行人基本情况 | 情况 | 内容 | | --- | --- | | 发行人名称 | 南京诺唯赞生物科技股份有限公司 | | 证券代码 | 688105.SH | | 注册资本 | 397,734,544 元 | | 注册地址 | 江苏省南京经济技术开发区科创路红枫科技园 C1-2 栋东段 1-6 层 | | 主要办公地址 | 江苏省南京经济技术开发区科创路红枫科技园 D2 栋 | | 法定代表人 | 曹林 | | 实际控制人 | 曹林、段颖 | ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company's revenue for 2024 reached 1.378 billion yuan, a year-on-year increase of 7.15%, while the net profit attributable to the parent company was -18 million yuan, a year-on-year increase of 74.5% [1][2]. - The growth in revenue is driven by the successful launch of new life science products and the expansion into overseas markets, while the profit growth outpaced revenue growth mainly due to a decrease in asset impairment losses [2][3]. - The company is actively pursuing a strategic transformation focusing on downstream major products, with successful advancements in respiratory, Alzheimer's disease blood testing, and GLP-1 businesses, which opens up long-term growth potential [1][3]. Financial Performance Summary - In 2024, the life sciences segment achieved a revenue growth of approximately 19%, with overseas revenue reaching 101 million yuan, a year-on-year increase of about 122% [3]. - The gross profit margin for 2024 was 69.97%, with a slight decrease of 1.08 percentage points year-on-year [2]. - The company expects revenues of 1.517 billion, 1.742 billion, and 2.011 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 10.1%, 14.8%, and 15.4% [4][5]. Business Segment Insights - The overseas business significantly contributed to growth, with a gross margin of 81%, which is higher than the domestic market [3]. - The company has strategically focused on major downstream products, achieving certifications for several respiratory products and making progress in the commercialization of the GLP-1 business [3]. Earnings Forecast - The forecast for net profit attributable to the parent company for 2025, 2026, and 2027 is 97 million, 121 million, and 151 million yuan, respectively, with substantial growth expected in 2025 at 634.1% year-on-year [4][5].